ATrain Education

 

Continuing Education for Health Professionals

Cannabis (Marijuana) for Medical Use

Module 10

References and Suggested Reading

References

Abel EL. (1980). Marihuana: The First Twelve Thousand Years. New York: McGraw-Hill.

Abrahamov A, Abrahamov A, Mechoulam R. (1995). An efficient new cannabinoid antiemetic in pediatric oncology. Life Sciences 56(23–24):2097–2102.

Abrams D. (2010). Cannabinoid: opioid reactions. Presentation at The Sixth National Clinical Conference on Cannabis Therapeutics, April 17, 2010; co-sponsored by Patients Out of Time and the UCSF School of Medicine; held at the Crowne Plaza Hotel, Warwick, RI.

Abrams D. (2002). Cannabis use with AIDS patients. Presentation at The Second National Clinical Conference on Cannabis Therapeutics, May 3, 2002; co-sponsored by Patients Out of Time and the Oregon Department of Human Services, Health Services; held at the Holiday Inn, Portland, OR.

Abrams DI, Hilton JF, Leiser RJ, et al. (2003). Short-term effects of cannabinoids in patients with HIV-1 infection: A randomized, placebo-controlled clinical trial. Annals of Internal Medicine 139: 258–66.

Aldrich M. (1997). History of therapeutic cannabis. In ML Mathre (Ed.), Cannabis in Medical Practice: A Legal, Historical, and Pharmacological Overview of the Therapeutic Use of Marijuana (pp. 35–55). Jefferson, NC: McFarland.

Appendino G, Gibbons S, Giana A, et al. (2008). Antibacterial cannabinoids from Cannabis sativa: A structure-activity study. Journal of Natural Products 71:1427–30.

Bachhuber, MA, Saloner B, Cunningham, CO, & Barry, CL (2014). Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010. JAMA Internal Medicine. 174(10: 1668-1673.

Blumgartin, AS. (1919). Materia Medica for Nurses, 2nd Ed. New York: MacMillan.

Bonnie RJ, Whitebread II (CH). (1974). The Marihuana Conviction: A History of Marihuana Prohibition in the United States. Charlottesville: University Press of Virginia.

Chan PC, Sills RC, Braun AG, et al. (1996). Toxicity and carcinogenicity of delta-9-tetrahydrocannabinol in Fischer rats and B6C3F1 mice. Fundamental and Applied Toxicology 30(1):109–17.

Craker L. (2010). Chasing the rainbow: Medical cannabis and the struggle to break the NIDA monopoly. Presentation at The Sixth National Clinical Conference on Cannabis Therapeutics, April 17, 2010; co-sponsored by Patients Out of Time and the UCSF School of Medicine; held at the Crowne Plaza Hotel, Warwick, RI.

Crippa J. (2010). Cannabidiol for the treatment of neuropsychiatric disorders: Past, present and future. Presentation at The Sixth National Clinical Conference on Cannabis Therapeutics, April 17, 2010; co-sponsored by Patients Out of Time and the UCSF School of Medicine; held at the Crowne Plaza Hotel, Warwick, RI.

Cushing R. (March 29, 2001). Pot shrinks tumors; government knew in ’74. San Antonio Current, TX.

Devane WA, Dysarz FA III, Johnson MR, et al. (1988). Determination and characterization of a cannabinoid receptor in rat brain. Molecular Pharmacology 34:605–13.

Devane WA, Hanus L, Breuer A, et al. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946–49.

Di Marzo V, Melck D, Bisogno T, De Petrocellis L. (1998). Endocannabinoids: Endogenous cannabinoid receptor ligands with neruomodulatory action. Trends in Neuroscienc. 21: 521–28.

Diagnostic and Statistical Manual of Mental Disorders (DSM-V). (2013).

Dowell D, Haegerich TM, Chou R. (2016). CDC Guidelines for Prescribing Opioids for Chronic Pain, United States 2016. MMWR Recomm Rep 2016;65:1–49. DOI: http://dx.doi.org/10.15585/mmwr.rr6501e1.

Dreher M. (1997). Cannabis and pregnancy. In ML Mathre (Ed.), Cannabis in Medical Practice: A Legal, Historical and Pharmacological Overview of the therapeutic Use of Marijuana (pp. 159–70). Jefferson, NC: McFarland.

Freimuth N, Ramer R, Burkhard H. (2010). Anti-tumorigenic Effects of Cannabinoids Beyond Apoptosis. Perspectives in Pharmacology 332(2):336–44.

Fride E, Bregman T, Kirkham TC. (2005). Endocannabinoids and food intake: Newborn suckling and appetite regulation in adulthood. (Review). Exp Biol Med (Maywood) 230(4):225–34.

Frisher M, Crome I, Martino O, Croft P. (2009). Assessing the impact of cannabis use on trends in diagnosed schizophrenia in the United Kingdom from 1996 to 2005. Schizophr Res 113(2-3):123.

Grotenhermen F. (2007) The toxicology of cannabis and cannabis prohibition. Chemistry and Biodiversity 4:1744–69.

Grotenhermen F. (2005). Cannabinoids. Current Drug Targets—CNS and Neurological Disorders 4:507–30.

Grotenhermen F, Russo E. (Eds.) (2002). Cannabis and Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential. NY: Haworth Integrative Healing Press.

Grucza RA, Agrawal A, Krauss MJ, et al. (2016). Recent trends in the prevalence of marijuana use and associated disorders in the United States. JAMA Psychiatry 73(3): 300–301.

Hall W, Room R, Bondy S. (1999). Comparing the health and psychological risks of alcohol, cannabis, nicotine and opiate use. In: Kalant H, Corrigan W, Hall W, Smart R, eds. The health effects of cannabis pp. 477–508. Toronto: Addiction Research Foundation.

Hampson AJ, Axelrod J, Grimaldi M. (2003). Cannabinoids as Antioxidants and Neuroprotectants. Patent No. US 6,630,507 B1. Date: 10/7/2003. U.S. Patent and Trademark Office.

Hashibe M, Morgenstern H, Cui Y, et al. (2006). Marijuana use and the risk of lung and upper aerodigestive tract cancers: Results of a population-based case-controlled study. Cancer Epidemiological Biomarkers Prevention 15(10):1829–34.

Henningfield JE, Benowitz NL. (1994, August 2). In Hilts PJ: Is Nocotine Addictive? It Depends of the Criteria You Use. The New York Times (p. C3).

Herzode C, Roudot-Thoraval F, Nguyen S, et al. (2005). Daily cannabis smoking as a risk factor for fibrosis progression in chronic hepatitis C. Hepatology 42(1):63–71.

Holland J. (Ed.). (2010). The Pot Book: a Complete Guide to Cannabis. Rochester, VT: Park Street Press.

Izzo AA, Borrelli F, Capasso R, et al. (2009). Non-psychotropic plant cannabinoids: New therapeutic opportunities from an ancient herb. Trends in Pharmacological Sciences 30(10):515–27.

Joy JE, Watson SJ, Benson JA. (1999). Marijuana and Medicine: Assessing the Science Base. Washington, DC: National Academy Press (Institute of Medicine). ISBN 0-309-07155-0.

Lucas P. (2004). British Columbia Patient Surveys. Presentation at The Third National Clinical Conference on Cannabis Therapeutics, May 22, 2004; co-sponsored by Patients Out of Time and the University of Virginia Schools of Medicine, Nursing, and Law; held at the Omni Hotel, Charlottesville, VA.

Macleod J, Davey Smith G, Hickman, M. (2006). Does cannabis use cause schizophrenia? Lancet 367(9516), 1055.

Martin M, Rosenthal E, Carter G. (2011). Medical Marijuana 101. Quick American Publishing: Oakland, CA.

Mathre ML. (1985). Marijuana Disclosure to Health Care Professionals. Unpublished master’s thesis. Case Western Reserve University, Cleveland, Ohio.

McPartland J. (2008). The endocannabinoid system: An osteopathic perspective. JAOA 108(10):586–600.

McPartland JM, Russo E.B. (2001). Cannabis and cannabis extracts: Greater than the sum of their parts? Journal of Cannabis Therapeutics 1(3–4), 103–32.

Mechoulam R. (2010a). Head trauma, osteoporosis, and Alzheimer’s disease—an unexpected trio. Presentation at The Sixth National Clinical Conference on Cannabis Therapeutics, April 17, 2010; co-sponsored by Patients Out of Time and the UCSF School of Medicine; held at the Crowne Plaza Hotel, Warwick, RI.

Mechoulam R. (2010b). Cannabis: Opening new vistas in both therapy and chemical biology. Presentation at The Sixth National Clinical Conference on Cannabis Therapeutics, April 16, 2010; co-sponsored by Patients Out of Time and the UCSF School of Medicine; held at the Crowne Plaza Hotel, Warwick, RI.

Melamede R. (2006). Cannabinoids and the Physics of Life. Presentation at The Fourth National Clinical Conference on Cannabis Therapeutics, April 7, 2006; co-sponsored by Patients Out of Time and UCSF School of Medicine; held at Santa Barbara City College, Santa Barbara, CA.

Munro S, Thomas KL, Abu-Shaar M. (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature (London). 365:61–65.

Munson AE, Harris LS, Friedman MA, et al. (1975). Antineoplastic activity of cannabinoids. Journal of the National Cancer Institute 55(3): 597–602.

National Commission on Marihuana and Drug Abuse. (1972). Marihuana: A Signal of Misunderstanding. New York: New American Library.

New Mexico Department of Health. (2015). Medical Cannabis Program Statistics as of 6/30/15. Retrieved July 30, 2015 from http://nmhealth.org/publication/view/report/1549/.

Oregon Health Authority. (2015). Oregon Medical Marijuana Program Statistics. Retrieved January 1, 2016 from http://public.health.oregon.gov/DiseasesConditions/ChronicDisease/MedicalMarijuanaProgram/Pages/data.aspx.

Pacher P, Bátkai S, Kunos G. (2006). The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacological Reviews 58(3):389–462.

Pertwee, R (Ed.) (2014). Handbook of Cannabis. Oxford: Oxford University Press.

Plasse T. (2002). Antiemetic effects of cannabinoids. In: Grotenhermen F and Russo E. (Eds.), Cannabis and Cannabinoids: Pharmacology, Toxicology and Therapeutic Potential (pp. 165–80). New York: Haworth Integrative Healing Press.

Randall R. (Ed.). (1988). Marijuana, Medicine, and the Law. Washington, DC: Galen Press.

Randall R, O’Leary A. (1998). Marijuana Rx: The Patients’ Fight for Medicinal Pot. New York: Thunder’s Mouth Press.

Reiman A. (2008). Compassion Clubs of California. Presented at The Fifth National Clinical Conference on Cannabis Therapeutics, April 5, 2008; co-sponsored by Patients Out of Time and the UCSF School of Medicine; held at Asilomar Conference Grounds, Pacific Grove, CA.

Rhode Island Department of Health. (2013). Medical Marijuana Program Patients by Diagnosis in Rhode Island, 2013. Retrieved July 29, 2013 from http://www.health.ri.gov/publications/programreports/MedicalMarijuana2013.pdf.

Richmond L. (Writer, Director). (2010). What if Cannabis Cured Cancer (DVD). Len Richmond Films.

Russo EB, Guy GW, Robson PJ. (2007). Cannabis, pain, and sleep: Lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine. Chemistry and Biodiversity 4:1729–43.

Russo E. (2004). Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome, and other treatment-resistant conditions? Neuroendocrinology Letters 25(1–2): 31–39.

Schnelle M, Strasser F. (2002) Anorexia and cachexia. In Grotenhermen F and Russo E. (Eds.), Cannabis and Cannabinoids: Pharmacology, Toxicology and Therapeutic Potential (pp. 153–64). New York: Haworth Integrative Healing Press.

Sidney S, Beck JE, Tekawa IS, et al. (1997). Marijuana use and mortality. American Journal of Public Health 87(4):585–90.

Sylvestor D, et al. (2006). Cannabis use improves retention and virological outcomes in patients treated for hepatitis C. European Journal of Gastroenterology and Hepatology. 18:1057–63.

Takahashi R. (2010). Cannabinoids and adverse memories in animals: Novel perspectives in the treatment of PRS(d). Presentation at The Sixth National Clinical Conference on Cannabis Therapeutics, April 17, 2010; co-sponsored by Patients Out of Time and the UCSF School of Medicine; held at the Crowne Plaza Hotel, Warwick, RI.

Tashkin DP. (2008). Does regular marijuana smoking lead to pulmonary or pulmonary-related disease (COPD, lung cancer, pneumonia)?: Cohort- and population-based studies. Presented at The Fifth National Clinical Conference on Cannabis Therapeutics, April 4, 2008; co-sponsored by Patients Out of Time and the UCSF School of Medicine; held at Asilomar Conference Grounds, Pacific Grove, CA.

Teesson M, Lynskey M, Manor B, Baillie A. (2002). The structure of cannabis dependence in the community. Drug and Alcohol Dependence 68:255–62.

United States Congress. (1970). Controlled Substances Act (P.L. 91-513, 84 Stat. 1242). Retrieved June 29, 2011 from http://www.enotes.com/major-acts-congress/controlled-substances-act.

Velasco G, Sanchez C & Guzman M. Towards the use of cannabinoids as antitumour agents. Nature Reviews Cancer. Online 4 May 2012; doi:10.1038/nrc3247.

Weil A, Rosen W. (1993). From Chocolate to Morphine: Everything You Need to Know About Mind-Altering Drugs. Boston: Houghton Mifflin.

West M. (1997). The use of certain cannabis derivatives (Canasol) in glaucoma. In ML Mathre (Ed.), Cannabis in Medical Practice: A Legal, Historical, and Pharmacological Overview of the Therapeutic Use of Marijuana (pp.103–11). Jefferson, NC: McFarland.

Wu T-C, Tashkin DP, Djahed B, Rose JE. (1988). Pulmonary hazards of smoking marijuana as compared with tobacco. New England Journal of Medicine 318(6):347–51.

Young FL, and U.S. Department of Justice, Drug Enforcement Administration (DOJ/DEA). (1988, September 6). In the Matter of Marijuana Rescheduling Petition (Docket No. 86-22). Opinion and Recommended Ruling, Findings of Fact, Conclusions of Law and Decision of the administrative law judge Francis L. Young.

Zimmer L, Morgan JP. (1997). Marijuana Myths, Marijuana Facts. New York: The Lindesmith Center.

Suggested Reading

Anthony JC, Warner LA, Kessler RC. (1994). Comparative epidemiology of dependence on tobacco, alcohol, controlled substances and inhalants: Basic findings from the National Comorbidity Survey. Experimental and Clinical Psychopharmacology 2:244–68.

Bonnie RJ, Whitebread II. (1974). The Marihuana Conviction: A History of Marihuana Prohibition in the United States (chapter). Charlottesville: University Press of Virginia.

Gerdeman G. (2010). Cannabinoids and the neurobiology of reward, habit formation, and addiction. Presentation at The Sixth National Clinical Conference on Cannabis Therapeutics, April 16, 2010; co-sponsored by Patients Out of Time and the UCSF School of Medicine; held at the Crowne Plaza Hotel, Warwick, RI.

Grotenhermen F, Russo E. (Eds.) (2002). Cannabis and Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential. New York: Haworth Integrative Healing Press.

Joy JE, Watson SJ, Benson JA. (1999). Marijuana and Medication: Assessing the Science Base. Washington, DC: National Academy Press (Institute of Medication). ISBN 0-309-07155-0.

Lee M. (2012). Smoke Signals: A Social History of Marijuana—Medical, Recreational, and Scientific. New York: Scribner.

Mathre ML. (Ed.) (1997). Cannabis in Medical Practice: A Legal, Historical and Pharmacological Overview of the Therapeutic Use of Marijuana. Jefferson, NC: McFarland & Company.

Russo EB, Mathre ML, Byrne A, et al. (2002). Chronic cannabis use in the Compassionate Investigational New Drug Program: An examination of benefits and adverse effects of legal clinical cannabis. Journal of Cannabis Therapeutics 2(1), 3–57.

Russo E, Dreher M, Mathre ML. (Eds.). (2003). Women and cannabis: Medication, science, and sociology. Binghamton, NY: Haworth Integrative Healing Press.

Russo EB, Grotenhermen F. (Eds.) (2006). Handbook of Cannabis Therapeutics: From Bench to Bedside. New York: Haworth Integrative Healing Press.

Werner C. (2011). Marijuana Gateway to Health: How Cannabis Protects Us from Cancer and Alzheimer’s Disease. San Francisco: Dachstar Press.

    Instructions
  • Online
  • Study the course, take the test, register and pay, print your certificate. Done!

  • Print Option
  • Click "Print Option" to print a hard copy with mail-in instructions.

  • Take the Test